Current Oncology Reports

, 16:378

When and When Not To Use Testosterone for Palliation in Cancer Care

Palliative Medicine (A Jatoi, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Palliative Medicine

Abstract

Hypogonadism is common throughout the illness trajectory of patients with cancer. About two thirds of male patients with advanced cancer have hypothalamic–pituitary–gonadal dysfunction and low testosterone levels. Chronic inflammation, comorbidities, cachexia, chemotherapy, and medications such as opioids, megestrol acetate, and corticosteroids contribute to primary and secondary hypogonadism. Studies have reported increased symptom burden, diminished quality of life, and poor prognosis associated with low testosterone levels in males with cancer. The Endocrine Society has published clinical practice guidelines for replacing testosterone in symptomatic patients with chronic illness and in patients receiving opioids; however, the role of testosterone therapy specifically in patients with cancer is not addressed. This review explores the potential benefits and limitations of testosterone replacement on the basis of current evidence.

Keywords

Hypogonadism Cancer Testosterone Endocrine Palliative medicine Oncology Testosterone replacement Low testosterone Low testosterone, males Low testosterone, cancer Males with cancer Chemotherapy Opioids Gonadal dysfunction Hypothalamic–pituitary–gonadal dysfunction Testosterone replacement, Limitations Symptom management Advanced cancer Quality of life 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Strasser F, Palmer JL, Schover LR, Yusuf SW, Pisters K, Vassilopoulou-Sellin R, et al. The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer. 2006;107(12):2949–57.PubMedCrossRefGoogle Scholar
  2. 2.
    Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Chlebowski RT, Heber D. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res. 1982;42(6):2495–8.PubMedGoogle Scholar
  4. 4.
    Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. J Pain Symptom Manag. 2003;26(5):1055–61.CrossRefGoogle Scholar
  5. 5.
    Del Fabbro E, Hui D, Nooruddin ZI, Dalal S, Dev R, Freer G, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manag. 2010;39(6):1016–24. doi:10.1016/j.jpainsymman.2009.09.021.CrossRefGoogle Scholar
  6. 6.
    Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, et al. Hypogonadism in male patients with cancer. Cancer. 2006;106(12):2583–91.PubMedCrossRefGoogle Scholar
  7. 7.
    Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab. 2008;93(6):2042–9. doi:10.1210/jc.2007-2595.PubMedCrossRefGoogle Scholar
  8. 8.
    Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf). 2011;74(3):289–93. doi:10.1111/j.1365-2265.2010.03939.x.CrossRefGoogle Scholar
  9. 9.
    Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010;95(6):2536–59. doi:10.1210/jc.2009-2354.PubMedCrossRefGoogle Scholar
  10. 10.
    Vigano A, Piccioni M, Trutschnigg B, Hornby L, Chaudhury P, Kilgour R. Male hypogonadism associated with advanced cancer: a systematic review. Lancet Oncol. 2010;11(7):679–84. doi:10.1016/S1470-2045(10)70021-8.PubMedCrossRefGoogle Scholar
  11. 11.•
    Del Fabbro E, Garcia JM, Dev R, Hui D, Williams J, Engineer D, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Support Care Cancer. 2013;21(9):2599–607. doi:10.1007/s00520-013-1832-5. Improved performance status and fatigue with prolonged testosterone replacement were reported in patients with advanced cancer; however, the trial is limited by the very small sample size.
  12. 12.
    Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, et al. Testosterone replacement increases fat free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82(2):407–13.PubMedGoogle Scholar
  13. 13.
    Loizides E, Swierzewski MJ, O'neill C, Griesser J, Smith T. Early response time in sexual activity and mood following testosterone gel replacement in hypogonadal males from the Testim® START study. Rev Urol. 2004;6 Suppl 6:S16–21.PubMedCentralPubMedGoogle Scholar
  14. 14.
    Woolf PD, Hamill RW, McDonald JV, Lee LA, Kelly M. Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab. 1985;60(3):444–50.PubMedCrossRefGoogle Scholar
  15. 15.
    Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24(24):3979–83.Google Scholar
  16. 16.
    Greenfield DM, Walters SJ, Coleman RE, Hancock BW, Eastell R, Davies HA, et al. Prevalence and consequences of androgen deficiency in young male cancer survivors in a controlled cross-sectional study. J Clin Endocrinol Metab. 2007;92(9):3476–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Fleishman SB, Khan H, Homel P, Suhail MF, Strebel-Amrhein R, Mohammad F, et al. Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. J Clin Oncol. 2010;28(34):5054–60. doi:10.1200/JCO.2010.30.3818.PubMedCrossRefGoogle Scholar
  18. 18.•
    Burney BO, Hayes TG, Smiechowska J, Cardwell G, Papusha V, Bhargava P, et al. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab. 2012;97(5):E700–9. doi:10.1210/jc.2011-2387. Cancer cachexia patients have lower testosterone levels than noncachectic cancer patients.Google Scholar
  19. 19.
    Panizzon MS, Hauger R, Jacobson KC, Eaves LJ, York TP, Prom-Wormley E, et al. Genetic and environmental influences of daily and intra-individual variation in testosterone levels in middle-aged men. Psychoneuroendocrinology. 2013;38(10):2163–72. doi:10.1016/j.psyneuen.2013.04.003.PubMedCrossRefGoogle Scholar
  20. 20.
    Travison TG, Zhuang WV, Lunetta KL, Karasik D, Bhasin S, Kiel DP, et al. The heritability of circulating testosterone, oestradiol, oestrone and sex hormone binding globulin concentrations in men: the Framingham Heart Study. Clin Endocrinol (Oxf). 2014;80(2):277–82. doi:10.1111/cen.12260.PubMedCrossRefGoogle Scholar
  21. 21.
    Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB. The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. Clin Endocrinol Metab. 2009;94(3):907–13. doi:10.1210/jc.2008-1902.CrossRefGoogle Scholar
  22. 22.
    Bremner WJ, Vitiello MV, Prinz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal men. J Clin Endocrinol Metab. 1983;56(6):1278–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Bhasin S, Basaria S. Diagnosis and treatment of hypogonadism in men. Best Pract Res Clin Endocrinol Metab. 2011;25(2):251–70. doi:10.1016/j.beem.2010.12.002.PubMedCrossRefGoogle Scholar
  24. 24.
    Blick G, Khera M, Bhattacharya RK, Nguyen D, Kushner H, Miner MM. Testosterone replacement therapy outcomes among opioid users: the Testim registry in the United States (TRiUS). Pain Med. 2012;13(5):688–98. doi:10.1111/j.1526-4637.2012.01368.x.PubMedCrossRefGoogle Scholar
  25. 25.
    Aloisi AM, Buonocore M, Merlo L, Galandra C, Sotgiu A, Bacchella L, et al. Chronic pain therapy and hypothalamic-pituitary-adrenal axis impairment. Psychoneuroendocrinology. 2011;36(7):1032–9. doi:10.1016/j.psyneuen.2010.12.017.PubMedCrossRefGoogle Scholar
  26. 26.
    Rasmussen DD, Liu JH, Wolf PL, Yen SS. Endogenous opioid regulation of gonadotropin-releasing hormone release from the human fetal hypothalamus in vitro. J Clin Endocrinol Metab. 1983;57(5):881–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Fabbri A, Jannini EA, Gnessi L, Moretti C, Ulisse S, Franzese A, et al. Endorphins in male impotence: evidence for naltrexone stimulation of erectile activity in patient therapy. Psychoneuroendocrinology. 1989;14(1–2):103–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Skipworth RJ, Moses AG, Sangster K, Sturgeon CM, Voss AC, Fallon MT, et al. Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 2011;19(3):391–401. doi:10.1007/s00520-010-0832-y.PubMedCrossRefGoogle Scholar
  29. 29.
    Dev R, Del Fabbro E, Bruera E. Megestrol acetate treatment associated with symptomatic adrenal insufficiency and hypogonadism in male patients with cancer. Cancer. 2007;110(6):1173–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update. 2001;7:363–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, et al. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer. 2013;119(13):2383–90. doi:10.1002/cncr.28089.PubMedCrossRefGoogle Scholar
  32. 32.
    Pope Jr HG, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(1):105–11.PubMedCrossRefGoogle Scholar
  33. 33.
    Bhasin S, Enzlin P, Coviello A, Basson R. Sexual dysfunction in men and women with endocrine disorders. Lancet. 2007;369(9561):597–611.PubMedCrossRefGoogle Scholar
  34. 34.
    Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial for testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch Gen Psychiatry. 2000;57(2):141–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Cherrier MM, Matsumoto AM, Amory JK, Johnson M, Craft S, Peskind ER, et al. Characterization of verbal and spatial memory changes from moderate to supraphysiological increases in serum testosterone in healthy older men. Psychoneuroendocrinology. 2007;32(1):72–9.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Bhasin S, Calof OM, Storer TW, Lee ML, Mazer NA, Jasuja R, et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab. 2006;2(3):146–59.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Bhasin S, Storer TW, Javanbakht M, Berman N, Yarasheski KE, Phillips J, et al. Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. JAMA. 2000;283(6):763–70.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Munch TN, Zhang T, Willey J, Palmer JL, Bruera E. The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med. 2005;8(6):1144–9.PubMedCrossRefGoogle Scholar
  39. 39.
    Snyder PJ. Testosterone treatment of male hypogonadism. In: Matusumoto AM, Martin KA, editors. UpToDate. UpToDate, Waltham. 2013. http://www.uptodate.com/contents/testosterone-treatment-of-male-hypogonadism.
  40. 40.
    Westaby D, Ogle SJ, Paradinas FJ, Randell JB, Murray-Lyon IM. Liver damage from long-term methyltestosterone. Lancet. 1977;2(8032):262–3.PubMedGoogle Scholar
  41. 41.
    Dinsmore WW, Wyllie MG. The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men. BJU Int. 2012;110(2):162–9. doi:10.1111/j.1464-410X.2011.10837.x.PubMedCrossRefGoogle Scholar
  42. 42.
    Giagulli VA, Triggiani V, Corona G, Carbone D, Licchelli B, Tafaro E, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Curr Pharm Des. 2011;17(15):1500–11.PubMedCrossRefGoogle Scholar
  43. 43.
    Testosterone topical solution (Axiron) for hypogonadism. Med Lett Drugs Ther. 2011;53(1368):54–5.Google Scholar
  44. 44.
    Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab. 1999;84(10):3469–78.PubMedGoogle Scholar
  45. 45.
    Finkelstein JS, Lee H, Burnett-Bowie SA, Pallais JC, Yu EW, Borges LF, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011–22. doi:10.1056/NEJMoa1206168.PubMedCrossRefGoogle Scholar
  46. 46.
    Handelsman DJ. Mechanisms of action of testosterone—unraveling a Gordian knot. N Engl J Med. 2013;369(11):1058–9. doi:10.1056/NEJMe1305307.PubMedCrossRefGoogle Scholar
  47. 47.
    Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, Mullan RJ, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010;95(6):2560–75. doi:10.1210/jc.2009-2575.PubMedCrossRefGoogle Scholar
  48. 48.
    Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351–61.PubMedCrossRefGoogle Scholar
  49. 49.
    Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109–22. doi:10.1056/NEJMoa1000485.PubMedCentralPubMedCrossRefGoogle Scholar
  50. 50.
    Bhasin S. Female androgen deficiency syndrome: an unproven hypothesis. J Clin Endocrinol Metab. 2005;90(8):4870–2.CrossRefGoogle Scholar
  51. 51.
    Miller KK, Rosner W, Lee H, Hier J, Sesmilo G, Schoenfeld D, et al. Measurement of free testosterone in normal women and women with androgen deficiency: comparison of methods. J Clin Endocrinol Metab. 2004;89(2):525–33.PubMedCrossRefGoogle Scholar
  52. 52.
    Bolour S, Braunstein G. Testosterone therapy in women: a review. Int J Impot Res. 2005;17(5):399–408.PubMedCrossRefGoogle Scholar
  53. 53.
    Key T, Appleby P, Barnes I, Reeves G, Endogenous hormones and breast cancer collaborative group. Endogenous sex hormone and breast cancer in postmenopausal women: reananlysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606–16.PubMedCrossRefGoogle Scholar
  54. 54.
    Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, et al. Androgen therapy in women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2006;91(10):3697–710.PubMedCrossRefGoogle Scholar
  55. 55.
    Schover LR. Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk? Fertil Steril. 2008;90(1):129–40.PubMedCrossRefGoogle Scholar
  56. 56.
    Traish A, Guay AT, Spark RF. Testosterone Therapy in Women Study Group. Are the Endocrine Society's clinical practice guidelines on androgen therapy in women misguided? A commentary. J Sex Med. 2007;4(5):1223–34.PubMedCrossRefGoogle Scholar
  57. 57.
    Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med. 2005;165(14):1582–9.PubMedCrossRefGoogle Scholar
  58. 58.
    Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol. 2005;105(5 Pt 1):944–52.PubMedCrossRefGoogle Scholar
  59. 59.
    Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005–17. doi:10.1056/NEJMoa0707302.PubMedCrossRefGoogle Scholar
  60. 60.
    Dillon EL, Basra G, Horstman AM, Casperson SL, Randolph KM, Durham WJ, et al. Cancer cachexia and anabolic interventions: a case report. J Cachex Sarcopenia Muscle. 2012;3(4):253–63.CrossRefGoogle Scholar
  61. 61.
    Morgentaler A. Testosterone deficiency and prostate cancer: emerging recognition of an important and troubling relationship. Eur Urol. 2007;52(3):623–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Morgentaler A. Testosterone therapy in men with prostate cancer: scientific and ethical considerations. J Urol. 2013;189(1 Suppl):S26–33. doi:10.1016/j.juro.2012.11.028.PubMedCrossRefGoogle Scholar
  63. 63.
    Yamamoto S, Yonese J, Kawakami S, Ohkubo Y, Tatokoro M, Komai Y, et al. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy. Eur Urol. 2007;52(3):696–701.PubMedCrossRefGoogle Scholar
  64. 64.
    Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172(3):920–2.PubMedCrossRefGoogle Scholar
  65. 65.
    Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173(2):533–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013;190(2):639–44. doi:10.1016/j.juro.2013.02.002.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of Palliative Care and Rehabilitation MedicineThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Division of Hematology/Oncology and Palliative Care, Massey Cancer CenterVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations